###### Strengths and limitations of this study

-   This umbrella review is the first synthesis of systematic reviews and meta-analyses to consider the associations between *H. pylori* infection and various health outcomes.

-   These results provide recommendations about the relationships between *H. pylori* infection and various health outcomes.

-   The associations observed in the meta-analyses included in this umbrella review may reflect the uncertainty of most diseases related to *H. pylori* infection.

-   Only evidence derived from systematic reviews and meta-analyses was included in our umbrella review. Evidence from original observational studies and/or randomised controlled trials that were not included in the meta-analyses was beyond our scope of discussion. This condition might result in conclusion bias of association between *H. pylori* infection and human health.

Introduction {#s1}
============

*H. pylori* is a Gram-negative bacterium that affects human health worldwide, and its prevalence ranges from 50.8% to 84%.[@R1] Earlier studies demonstrated that *H. pylori* infection contributes to the development of several digestive diseases (e.g. gastric cancer,[@R5] peptic ulcer disease (PUD)[@R7] and dyspepsia).[@R8] These conclusions were supported by recent studies.[@R9] Over the last 20 years, the associations between *H. pylori* infection and a sequence of non-digestive disorders have been investigated extensively. Multiple studies and meta-analyses have revealed that *H. pylori* infection is harmful to human health by increasing the risk of diverse diseases, including cancers, cardiovascular and cerebrovascular diseases, respiratory disorders, endocrine diseases and neurocognitive disorders. Meta-analyses have further reported that *H. pylori* infection increases the risk of acquiring hepatocellular carcinoma (HCC) by more than 16-fold,[@R13] cholangiocarcinoma by approximately 9-fold[@R14] and myocardial infarction (MI) nearly 2-fold.[@R15] Subsequently, with further research on *H. pylori* infection, it may be beneficial to health in some conditions by decreasing the risk of diseases (e.g. asthma,[@R16] inflammatory bowel disease[@R17] and oesophageal cancer).[@R18] Therefore, the causal role of *H. pylori* infection in these diseases has been widely queried.

The observed associations between *H. pylori* infection and health outcomes can be causal, indicating that *H. pylori* infection elicits adverse effects on human health. However, the publication bias, scheme design defects or inconsistencies of studies can lead to a decrease in the strength and validity of evidence. Furthermore, confounding factors, such as age, sex, smoking or drinking status, can affect causality. The lack of adequate controls for confounders may cause reverse causality. Therefore, evidence from meta-analyses may also have uncertainty. If causal, the association of *H. pylori* infection and public health should be reconsidered, and the role of *H. pylori* infection in human health must be reanalysed. Once strong associations between *H. pylori* infection and diseases are confirmed, findings provide an important guidance both for conducting disease diagnosis and treatment. Therefore, the associations of *H. pylori* infection and health outcomes must be further evaluated.

To provide an overview of the length, validity and credibility of the evidence on the associations between *H. pylori* infection and human health outcomes, we systematically and comprehensively re-evaluated these pieces of evidence to make them concise for decision-makers and guideline developers. We conducted an umbrella review to estimate the findings and content of meta-analyses that investigated these associations and to estimate the evidence of potential bias and consistency of findings.

Methods {#s2}
=======

Literature search {#s2-1}
-----------------

Computerised searches on Embase, PubMed, Web of Science, Cochrane Database of Systematic Reviews, CNKI, VIP database and Wangfang database were independently and comprehensively performed by two researchers (Guangwen Chen and Mingbing Chen) to identify the systematic reviews and meta-analyses of epidemiological studies investigating the associations between *H. pylori* infection and diverse health outcomes. Studies published from inception to February 1, 2019 were collected using a comprehensive search strategy, and the language was limited to English and Chinese. Medical subject heading (MeSH) terms and free-text words were used: meta-analysis, meta analysis, meta-analyses, meta analyses, systematic review, *Helicobacter pylori*, *Campylobacter pylori*, Pylorus spirillum and *H. pylori*. The search strategies are described in [online supplementary appendix 1](#SP1){ref-type="supplementary-material"}. References from eligible systematic reviews were also manually reviewed. All identified publications were managed with EndNote X7. Two reviewers (Qingzeng Song and Jieru Xie) independently screened the titles, abstracts and full texts for eligible articles based on the inclusion and exclusion criteria. Any discrepancy was resolved by discussion, and all discrepancies that could not be resolved through a discussion were arbitrated by Sheng Xie.
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Eligibility criteria and exclusion criteria {#s2-2}
-------------------------------------------

Only systematic reviews and meta-analyses of epidemiological studies investigating the associations between *H. pylori* and multiple diseases were included in this umbrella review. The included systematic reviews and meta-analyses should present the data of pooled summary effects (i.e. relative risks (RRs), odds ratios (ORs), mean difference (MD), standard mean difference (SMD) and their 95% confidence intervals (CIs)), number of included studies, number of cases and participants, publication bias and heterogeneity. Table data (2×2) should be presented if pooled summary effects were unavailable. The population included was not limited to age, sex, ethnicity or country of origin. Articles were not limited to clinical setting, study region or research institution. When more than one meta-analyses were performed for the same review question, the concordance of the main conclusions was checked. If conclusions were inconsistent, the meta-analysis with the largest sample size and the latest date of publication was selected. The meta-analyses of interventional trials and diagnostic trials were unavailable for our research question. Conference abstracts on review questions were also excluded.

Patient and public involvement {#s2-3}
------------------------------

Our study is a review of literature, so no patient was involved.

Data extraction {#s2-4}
---------------

Data from each eligible systematic review and meta-analysis were independently extracted by two investigators (Liqun Li and Jinjing Tan). All of the results were carefully checked by a third investigator (Xiaoyan Huang). Any discrepancy was resolved by discussion, and all discrepancies were arbitrated by a fourth reviewer (Sheng Xie). The name of the first author, the year of publication, outcomes examined, the number of included studies, the total numbers of participants and cases, study design, study region and detection method of *H. pylori* were extracted by using a predesigned data extraction form. For each eligible systematic review and meta-analysis, the reported relative summary risk estimates (RRs, ORs, SMD or MD) and their 95% CIs were extracted. The p values of the overall pooled effects, Egger's test and Cochran Q test were extracted. The results of I^2^ were also extracted. However, if the eligible systematic reviews or meta-analyses did not assess the quality of the included studies, assessing the quality was beyond our task in this umbrella review. If systematic reviews or meta-analyses examined more than one health outcome of interest, each outcome was recorded separately. If the included meta-analyses did not present the results of pooled meta-analysis (RRs, ORs, SMD or MD), I^2^, Egger's test or publication bias, the 2×2 table data from studies included in those meta-analyses were extracted for reanalysis.

Assessment of methodological quality {#s2-5}
------------------------------------

The methodological quality of the included studies was independently assessed by two investigators (Liqun Li and Jianfeng Li) using AMSTAR 2 (A Measurement Tool to Assess systematic Reviews),[@R19] and the results were checked by a third investigator (Xiaoyan Huang) . Inconsistencies were resolved through a discussion or consultation with a fourth reviewer (Sheng Xie). AMSTAR 2 is a reliable, valid and critical assessment tool developed from AMSTAR in 2017.[@R19] It contains 16 checklists (7 critical checklists and 9 non-critical checklists) for assessing systematic reviews and meta-analyses, including randomised controlled trial (RCT) studies, observational studies on exposures or both. The rating criteria of AMSTAR 2 were as follows: zero or one non-critical weakness was defined as high quality; more than one non-critical weakness was defined as moderate quality; one critical flaw with or without non-critical weaknesses was defined as low quality; and more than one critical flaw with or without non-critical weaknesses was defined as critically low quality.

Assessment of the quality of evidence {#s2-6}
-------------------------------------

In this umbrella review, we used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system to evaluate the quality of evidence for each outcome.[@R22] The GRADE system includes five factors for downgrading and three factors for upgrading the quality of evidence. The baseline quality of evidence of health outcomes depends on the design of the primary studies. The summary estimate result of the random-effect model was used if potential heterogeneity was observed. Otherwise, the result of the fixed-effect model was used. When a serious or very serious defect could occur because of downgrading factors, the evidence quality was downgraded by one or two levels, respectively. If the effect was large (RR/OR either \>2.0 or \<0.5) or very large (RR/OR either\>5.0 or \<0.2), the evidence quality was upgraded by one level or two levels, respectively. If there was evidence that the influence of all plausible confouding would reduce a demonstrated effect or suggest a apurious effect when results show no effect, the evidence quality was upgraded by one level.The rating criteria of GRADE[@R22] were as follows: the primary evidence quality of an observational study was considered 'low'; the evidence quality was downgraded to 'very low quality' by downgrading one level, upgraded to 'moderate quality' by increasing one level and upgraded to 'high quality' by increasing two levels. The GRADE system approach classifies the evidence quality of outcomes from eligible articles as high, moderate, low and very low.[@R22] GRADE classification was independently performed by two investigators (Liqun Li and Jinjing Tan), and the results were checked by a third researcher (Xiaoyan Huang). Any discrepancy was resolved via a discussion, and all discrepancies that could not be resolved through a discussion were arbitrated by Sheng Xie.

Data analysis {#s2-7}
-------------

If the included meta-analyses did not present results of pooled meta-analysis, they were reanalysed. For example, a study was reanalysed if it did not present the results of pooled meta-analysis (RRs, ORs, SMD or MD), Egger's test, publication bias or I^2^. The heterogeneity between different studies was assessed using the I^2^ metric of inconsistency and the p value of χ^2^ based on the Cochran Q test. If heterogeneity was observed, a random-effect model was used to calculate the relative summary risk estimates. Otherwise, a fixed-effect model was used.[@R24] Publication bias was estimated by using Egger's test.[@R26] The overall effects of pooled meta-analysis, heterogeneity was considered significant at p value \<0.1. Publication bias was cnsidered significant at p\<0.1. Statistical analyses were conducted using Stata V.15.

Results {#s3}
=======

Description of the meta-analyses {#s3-1}
--------------------------------

Overall, 3036 articles that met our search criteria were first identified from the seven databases. Sixty articles[@R9] [@R27] of observational studies were finally selected, covering 88 unique outcomes ([figure 1](#F1){ref-type="fig"}). Fifty-four meta-analyses[@R10] were reanalysed because they did not present all of the results of estimates (i.e. OR, RR), Egger's test, I^2^ or publication bias. These 60 eligible non-overlapping meta-analyses are summarised in [table 1](#T1){ref-type="table"}. A total of 1239 individual study estimates were included in the included meta-analyses. Various measurement methods, including serology, histology, rapid urease test and 18 other detection methods, were used to determine *H. pylori* positivity. A range of 2--79 study estimates were pooled per meta-analysis, and the median of the study estimate was 10. Among the 1239 individual studies, 274 (22%) were cross-sectional studies, 748 (60%) were case--control studies, 124 (10%) were cohort studies and 93 (8%) were mentioned as observational studies. Furthermore, 1 meta-analysis[@R62] did not present the number of participants, and 12 meta-analyses[@R27] did not present the number of cases. Among the meta-analyses that indicated the number of cases or participants, the median number of cases was 1032 (28--96 753) and the median number of participants was 3826 (222--377 976). A total of 76 meta-analyses included more than 1000 participants, 34 meta-analyses included more than 1000 cases and 11 meta-analyses included less than 300 cases. The 60 included articles were published from 2003 to 2019, 77% were published between 2014 and 2019, and the number of publication increased yearly before 2016 ([figure 2](#F2){ref-type="fig"}). Various health outcomes associated with *H. pylori* infection included cancer outcomes (n=12), cardiovascular and cerebrovascular diseases (n=8), respiratory disorders (n=3), endocrine disease (n=10), urological disease (n=2), digestive disorders (n=18), neurocognitive disorders (n=5), pregnancy-related disorders (n=9), ophthalmic diseases (n=2), thyroid disease (n=3), haematological disorders (n=3) and other outcomes (n=13) ([figure 3](#F3){ref-type="fig"}). A total of 23 articles conducted subgroup meta-analysis based on different study region ([table 2](#T2){ref-type="table"}). *H. pylori* infection was most harmful to Asians, followed by Europeans.
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###### 

Description of 60 meta-analyses of H. pylori infection and prevalence or incidence of diseases included in umbrella review

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Included meta-analyses                        Outcomes^¶^                                  HP detection\                                                     Number of studies    Number of participants   Number of cases   Type of metric        Relative risk (95% CI)   P value^\*^   P value^†^   I^2^ (%)   P value^‡^   Whether exist publication bias
                                                                                             method                                                                                                                                                                                                                              
  --------------------------------------------- -------------------------------------------- ----------------------------------------------------------------- -------------------- ------------------------ ----------------- --------------------- ------------------------ ------------- ------------ ---------- ------------ --------------------------------
  Cancer outcomes                                                                                                                                                                                                                                                                                                                

   Xuan *et al* [@R13]                          Hepatocellular carcinoma                     HP DNA                                                            9 CCS; 1 CSS         522                      129               OR                    16.52 (6.63 to 41.12)    0.00          0.07         44         0            Yes

   Mounika\                                     Lung cancer                                  ELISA                                                             5 CCS;1 PNCCS;\      17 951                   16 244            OR                    2.29 (1.34 to 3.91)      0.032         \<0.01       83.9       NA           No^§^
  [@R44]                                                                                                                                                       1 PCS                                                                                                                                                             

   Xie *et al* [@R18]                           ESCC in Eastern populations                  S; H; R; His ^+^; HpSe ^+^                                        16 OS                7665                     1961              OR                    0.66 (0.43 to 0.89)      NA            \<0.01       74.5       0.42         No

   Xie *et al* [@R18]                           EAC in the overall population                S; H; U; His ^+^; HpSe ^+^                                        15 OS                6035                     1330              OR                    0.59 (0.51 to 0.68)      NA            0.13         29.9       0.37         No

   Wang *et al* [@R58]                          Colorectal adenomatous polyp                 S; H; several                                                     12 CS                2678                     1783              OR                    1.89 (1.59 to 2.25)      0             0.10         35.9       0.61         No

   Xiao *et al* [@R14]                          Cholangiocarcinoma                           PCR; ELISA; WB                                                    10 CCS               489                      220               OR                    8.88 (3.67 to 21.49)     0             0.02         56         0.01         Yes

   Dong and Hao[@R75]                           Colorectal cancer                            IgG; UBT; CagA                                                    21 CCS; 2 CSS        182 561                  24 295            OR                    1.42 (1.38 to 1.46)      0             \<0.01       71         0.74         No

   Zhou *et al* [@R74]                          Laryngeal carcinoma                          ELISA; H; PCR                                                     11 CCS               1030                     418               OR                    2.87 (1.7 to 4.84)       0             0.00         67.1       0.62         No

   Liu[@R28]                                    Colon neoplasia                              IgG; IgA; UBT; H; CaA                                             24 CCS; 7 CSS;\      25 897                   12 145            OR                    1.63 (1.39 to 1.90)      0             \<0.01       80         0.14         No
                                                                                                                                                               2 NCCS                                                                                                                                                            

   Li *et al* [@R12]                            Gastric cancer                               WB; Chip; ELISA;\                                                 10 CCS               1094                     664               OR                    2.78 (1.98 to 3.89)      0             0.23         22.8       0.1          No
                                                                                             neutralisation assay; EIA                                                                                                                                                                                                           

   Ma *et al* [@R42]                            Oesophagogastric junction adenocarcinoma     NA                                                                9 CCS; 4 PCS         5547                     2893              OR                    0.95 (0.06 to 1.36)      0.769         0.00         78         0.61         No

   Liu *et al* [@R41]                           Pancreatic cancer                            ELISA                                                             6 NCCS; 2 PCS        44 193                   NA                OR                    1.09 (0.81 to 1.47)      0.58          \<0.01       76         0.59         No

  Cardiovascular and cerebrovascular diseases                                                                                                                                                                                                                                                                                    

   Pasceri *et al* [@R47]                       Ischaemic heart disease                      CagA                                                              3 PCS                2140                     966               OR                    1.26 (1.05 to 1.51)      \<0.00001     0.01         53         NA           No^§^

   Pasceri *et al* [@R47]                       Cerebral ischaemia                           CagA                                                              4 RCCS               1103                     446               OR                    2.43 (1.89 to 3.13)      \<0.00001     0.43         0          NA           No^§^

   Wang *et al* [@R55]                          Diabetic IHD                                 S; H                                                              5 CS                 1805                     469               RR                    1.12 (0.95 to 1.32)      0.172         0.14         42.30      0.21         No

   Liu *et al* [@R15]                           Myocardial infarction                        NA                                                                19 CSS; 7 PCS        21 960                   11 156            OR                    1.73 (1.37 to 2.17)      0             0.00         87.9       0.71         No

   Chen *et al* [@R48]                          Coronary heart disease                       NA                                                                12 CSS; 5 PCS;\      17 514                   9165              OR                    1.64 (1.22 to 2.23)      0.001         \<0.01       90         0.58         No
                                                                                                                                                               1 NA                                                                                                                                                              

   Saburi *et al* [@R43]                        Atherosclerosis                              PCR                                                               4 CCS                222                      102               OR                    5.98 (0.69 to 51.99)     0.105         0.03         67.6       0.04         Yes

   Yan *et al* [@R65]                           Arrhythmia                                   IgG; ^13^C-UBT; UBT                                               7 CCS                2014                     1032              OR                    1.80 (1.08 to 2.99)      0.024         \<0.001      80         0.28         No

   Dong *et al* [@R76]                          Carotid intima thickness                     NA                                                                9 CCS                1370                     694               SMD                   0.80 (0.69 to 0.92)      \<0.01        0.00         89.7       NA           No^§^

  Respiratory disorders                                                                                                                                                                                                                                                                                                          

   Wang *et al* [@R57]                          COPD                                         S; ^14^C-UBT                                                      9 CCS                9465                     3192              OR                    2.25 (1.73 to 2.92)      0             0.00         75.5       0.27         No

   Wang *et al* [@R57]                          Chronic bronchitis                           S; ^14^C-UBT                                                      5 CCS                5674                     1824              OR                    1.57 (1.33 to 1.86)      0             0.04         58.2       0.51         No

   Chen *et al* [@R16]                          Asthma                                       SA; ELISA; IgG;\                                                  8 CCS; 16 CSS        53 947                   5648              OR                    0.83 (0.74 to 0.94)      0.002         0.00         53.4       0.67         No
                                                                                             ^13^C-UBT                                                                                                                                                                                                                           

  Endocrine disease                                                                                                                                                                                                                                                                                                              

   Upala *et al* [@R54]                         Metabolic syndrome                           S; R; H; SA;\                                                     5 CSS; 1 CS          19 771                   NA                OR                    1.34 (1.17 to 1.53)      NA            \<0.01       39         0.92         No
                                                                                             UBT; biopsy                                                                                                                                                                                                                         

   Upala *et al* [@R54]                         Fasting blood glucose                        S; R; H; SA                                                       11 CSS; 3 CS         7905                     NA                MD                    2.37 (0.98 to 3.77)      NA            0.04         55         0.92         No

   Upala *et al* [@R54]                         HDL-C                                        UBT; biopsy                                                       9 CSS; 3 CS          7701                     NA                MD                    -2.43 (-3.75 to -1.12)   NA            \<0.01       92         0.92         No

   Upala *et al* [@R54]                         Triglyceride level                           S; R; H; SA                                                       8 CSS; 3 CS          7596                     NA                MD                    8.12 (3.05 to 13.2)      NA            0.04         71         0.92         No

   Upala *et al* [@R54]                         Systolic blood pressure                      UBT; biopsy; culture                                              5 CSS; 1 CS          7172                     NA                MD                    2.88 (0.20 to 5.57)      NA            0.01         89         0.92         No

   Upala *et al* [@R54]                         Body mass index                              S; R; H; SA                                                       8 CSS; 2 CS          10 707                   NA                MD                    0.30 (0.01 to 0.58)      NA            \<0.01       57         0.92         No

   Upala *et al* [@R54]                         HOMA-IR                                      UBT; biopsy                                                       7 CSS; 3 CS          7935                     NA                MD                    0.38 (0.03 to 0.73)      NA            0.03         85         0.92         No

   Li *et al* [@R39]                            DM                                           ^13^C-UBT; R; ^14^C-UBT; SA; biopsy;\                             8 CSS; 68 CCS;\      57 397                   28 542            OR                    1.69 (1.47 to 1.95)      0             \<0.00001    86         0            Yes
                                                                                             culture; H                                                        3 PCS                                                                                                                                                             

   Li *et al* [@R39]                            T2 DM                                        ^13^C-UBT; R; ^14^C-UBT; SA; biopsy;\                             8 CSS; 57 CCS;\      41 684                   21 286            OR                    2.05 (1.67 to 2.52)      0             \<0.00001    89         0            Yes
                                                                                             culture; H                                                        2 PCS                                                                                                                                                             

   Li *et al* [@R39]                            T1 DM                                        ^13^C-UBT; R; ^14^C-UBT; biopsy; H                                1 PCS; 11 CCS        3175                     969               OR                    1.23 (0.77 to 1.96)      0.499         \<0.00001    82         0.46         No

  Urological disease                                                                                                                                                                                                                                                                                                             

   Wang *et al* [@R56]                          Diabetic nephropathy                         ^13^C-UBT; ELISA; H                                               6 CCS                636                      211               OR                    1.6 (1.1 to 2.33)        0.018         0.44         0          0.98         No

   Wijarnpreecha *et al* [@R62]                 ESRD in adult                                A; H; R; UBT; SA;\                                                33 CSS               NA                       NA                RR                    0.71 (0.55 to 0.94)      NA            \<0.00001    79         NA           No^§^
                                                                                             culture                                                                                                                                                                                                                             

  Digestive disorders                                                                                                                                                                                                                                                                                                            

   Erőss *et al* [@R32]                         Barrett's oesophagus                         S; H; UBT; PCR; R; SA                                             70 CCS               91 656                   12 134            OR                    0.68 (0.58 to 0.79)      0             0.00         84         \<0.001      Yes

   Li *et al* [@R12]                            Gastric ulcer                                WB; Chip; ELISA;\                                                 8 CCS                517                      260               OR                    1.64 (1.02 to 2.62)      0.042         0.26         20.8       0.96         No
                                                                                             neutralisation assay; EIA                                                                                                                                                                                                           

   Li *et al* [@R12]                            Duodenal ulcer                               WB; Chip; ELISA;\                                                 17 CCS               2359                     1333              OR                    2.06 (1.50 to 2.84)      0             0.01         51.3       0.63         No
                                                                                             neutralisation assay; EIA                                                                                                                                                                                                           

   Cremonini *et al* [@R30]                     GERD in population with HP-negative status   R; S; biopsy; H; UBT; Gram stain;\                                14 CCS               2010                     1683              OR                    1.34 (1.15 to 1.55)      0             \<0.001      NA         NA           No^§^
                                                                                             culture; H&E; Giemsa stain                                                                                                                                                                                                          

   Weck and Brenner[@R11]                       Chronic atrophic gastritis                   NA                                                                34 OS                7726                     5048              OR                    6.37 (4.01 to 10.11)     0             0.00         91.2       0.01         Yes

   Zhou *et al* [@R73]                          Biliary lithiasis                            ELISA; PCR; culture                                               13 CCS               1333                     432               OR                    2.59 (1.21 to 5.55)      0.014         \<0.0001     69.5       0.18         No

   Shiota *et al* [@R10]                        Peptic ulcer disease                         PCR                                                               42 CCS               4601                     2524              OR                    1.25 (1.09 to 1.44)      0.002         0.39         4.6        0.78         No

   Jiang *et al* [@R37]                         Ammonia levels in cirrhotic patients         ^14^C-UBT; R; H; culture; IgG                                     6 OS                 396                      632               SMD                   0.34 (0.21 to 0.47)      NA            0.12         42.1       0.11         No

   Ford *et al* [@R9]                           Dyspepsia                                    NA                                                                13 CSS               25 305                   9010              OR                    1.18 (1.04 to 1.33)      NA            \<0.001      63         0.3          No

   Feng *et al* [@R33]                          Alcoholic cirrhosis in all population        R; UBT; H; ELISA                                                  8 CCS                14 226                   10053             OR                    0.82 (0.35 to 1.91)      0.648         0.00         84.5       0.67         No

   Feng *et al* [@R33]                          Alcoholic cirrhosis in European              R; H; ELISA                                                       3 CCS                1171                     516               OR                    2.14 (1.19 to 3.86)      0.011         0.31         15.5       0.74         No

   Wu *et al* [@R17]                            Inflammatory bowel disease                   IgG; UBT; H; culture                                              10 OS                3116                     1202              RR                    0.48 (0.43 to 0.54)      0             0.25         21         0.2          No

   Wang *et al* [@R60]                          Chronic hepatitis C                          PCR; S                                                            12 CCS               3826                     2185              OR                    2.93 (2.30 to 3.75)      0             0.05         45         0.31         No

   Wang *et al* [@R59]                          Chronic hepatitis B                          S                                                                 15 CCS               5129                     2845              OR                    3.17 (2.38 to 4.22)      0             0.00         77.9       0.02         Yes

   Wijarnpreecha *et al* [@R63]                 NAFLD                                        EIA; IgG; ^14^C-UBT; H; S; SA                                     5 CSS; 1 CCS         38 594                   NA                OR                    1.21 (1.07 to 1.37)      0.002         0.08         49         NA           No^§^

   Cen *et al* [@R27]                           Chronic cholecystitis and cholelithiasis     H; PCR; culture                                                   18 CCS               1544                     NA                OR                    3.02 (1.90 to 4.82)      NA            0.21         20.1       0.43         No

   Shah *et al* [@R49]                          Eosinophilic oesophagitis                    Biopsy; R; H; IgG; ELISA; EIA; H&E; SA; ^13^C-UBT                 5 CCS;\              371 274                  26 442            OR                    0.63 (0.51 to 0.78)      0.00          0.02         57.9       0.77         No
                                                                                                                                                               3 CS or CCS                                                                                                                                                       

   Shah *et al* [@R49]                          Oesophageal eosinophilia                     Biopsy; R; H; IgG; ELISA; EIA; H&E; SA; ^13^C-UBT                 5 CCS;\              377 976                  28 007            OR                    0.64 (0.52 to 0.78)      0.00          0.00         69.4       0.7          No
                                                                                                                                                               6 CS or CCS                                                                                                                                                       

  Neurocognitive disorders                                                                                                                                                                                                                                                                                                       

   Wang *et al* [@R55]                          Diabetic neuropathy                          S; H                                                              5 CS                 1607                     520               RR                    1.20 (1.03 to 1.40)      0.018         0.29         19.1       0.99         No

   Wang *et al* [@R61]                          Ischaemic stroke                             IgG; CagA; C-UBT                                                  13 CCS               4041                     NA                OR                    1.60 (1.21 to 2.11)      NA            0.00         65.2       0.01         Yes

   Yu *et al* [@R70]                            Stroke                                       S                                                                 6 CS; 4 CCS          166 041                  1769              OR                    0.96 (0.78 to 1.14)      NA            0.03         48         0.68         No

   Shindler-Itskovitch *et al* [@R51]           Dementia                                     Biopsy; IgG; IgA; R; H; CagA                                      1 CS; 6 CCS          86 606                   NA                OR                    1.71 (1.17 to 2.49)      0.01          \<0.001      76.1       0.33         No

   Shen *et al* [@R50]                          Parkinson's disease                          ELISA; PCR; ^13^C-UBT; H; prescriptions for HP eradication drug   6 CCS; 2 CSS         28 201                   1101              OR                    1.59 (1.37 to 1.85)      0             0.55         0          0.02         Yes

  Pregnancy-related disorders                                                                                                                                                                                                                                                                                                    

   Ng *et al* [@R45]                            Hyperemesis gravidarum                       Biopsy; H; ELISA; IgG; CagA;\                                     33 CCS; 4 CSS;\      10 289                   NA                OR                    1.35 (1.16 to 1.54)      \<0.01        0.06         28         0.76         No
                                                                                             EIA; ^13^C-UBT; SA                                                1 CS                                                                                                                                                              

   Zhan *et al* [@R72]                          Pre-eclampsia                                ELISA; CLIA; Heli‐Blot assay; SA; UBT; WB                         3 CS; 12 CCS;\       10 402                   1077              OR                    2.51 (1.18 to 3.34)      0             0.00         63         0.02         Yes
                                                                                                                                                               1 CSS                                                                                                                                                             

   Zhan *et al* [@R72]                          Fetal growth restriction                     Heli‐Blot assay; ELISA; SA                                        3 CCS; 2 CS          6009                     202               OR                    2.28 (1.21 to 4.32)      0.011         0.02         66         0.17         No

   Zhan *et al* [@R72]                          Gestational DM                               ELISA; SA; WB; UBT                                                2 CCS; 3 CS          3697                     270               OR                    2.03 (1.56 to 2.64)      0             0.81         0          0.77         No

   Zhan *et al* [@R72]                          Spontaneous abortion                         ELISA; SA                                                         2 CS; 3 CCS; 1 CSS   5909                     226               OR                    1.5 (1.05 to 2.14)       0.024         0.23         27         0.76         No

   Zhan *et al* [@R72]                          Birth defect                                 ELISA; CLIA                                                       1 CS; 2 CCS          737                      132               OR                    1.63 (1.05 to 2.54)      0.031         0.48         0          0.14         No

   Zhan *et al* [@R72]                          Stillbirth                                   SA; ELISA                                                         1 CS; 1 CCS          3008                     28                OR                    2.53 (0.79 to 8.13)      0.118         0.61         0          0.79         No

   Zhan *et al* [@R72]                          Low birth weight                             NA                                                                7 CS or CCS          10 121                   NA                OR                    1.35 (0.88 to 2.08)      NA            0.16         72         NA           Unclear

   Zhan *et al* [@R72]                          Premature delivery                           NA                                                                8 CS or CCS          12 356                   NA                OR                    1.35 (0.86 to 2.12)      NA            0.18         70         NA           Unclear

  Ophthalmic diseases                                                                                                                                                                                                                                                                                                            

   Wang *et al* [@R55]                          Diabetic retinopathy                         S; H                                                              7 CS                 1815                     406               RR                    1.32 (0.97 to 1.80)      0.058         0.04         55         0.27         No

   Zeng *et al* [@R71]                          Open-angle glaucoma                          H; IgG; ^13^C-UBT                                                 18 CCS               1580                     695               OR                    2.08 (1.42 to 3.04)      NA            \<0.001      63.6       0.36         No

  Thyroid disease                                                                                                                                                                                                                                                                                                                

   Hou *et al* [@R67]                           Autoimmune thyroid diseases                  ELISA; WB; UBT; SA                                                15 CCS               3046                     2408              OR                    2.25 (1.72 to 2.93)      0             0.00         61.6       0.68         No

   Hou *et al* [@R67]                           Grave's disease                              ELISA; SA; UBT                                                    5 CCS                917                      498               OR                    2.78 (1.68 to 4.61)      0             0.07         53.4       1.51         No

   Hou *et al* [@R67]                           Hashimoto's thyroiditis                      ELISA; SA; UBT; NR                                                8 CCS                1594                     872               OR                    2.16 (1.44 to 3.23)      0             0.00         68.2       0.51         No

  Haematological disorders                                                                                                                                                                                                                                                                                                       

   Hudak *et al* [@R35]                         Iron deficiency anaemia                      R; H; ^13^C-UBT; ^14^C-UBT;\                                      11 CSS; 3 CCS        15 905                   NA                OR                    1.72 (1.23 to 2.42)      NA            0.00         61.5       0.38         No
                                                                                             IgG; SA; IgA; gastroscopy                                                                                                                                                                                                           

   Hudak *et al* [@R35]                         Iron deficiency                              30 CSS                                                            23 521               NA                       OR                1.33 (1.15 to 1.54)   NA                       0.01          41.1         0.49       No           

   Hudak *et al* [@R35]                         Anaemia                                      23 CSS                                                            11 622               NA                       OR                1.15 (1.00 to 1.32)   NA                       0.01          NA           0.81       No           

  Other outcomes                                                                                                                                                                                                                                                                                                                 

   Nweneka and Prentice[@R46]                   Circulating ghrelin levels                   UBT; ELISA; S; H; culture; R; PCR                                 7 CS; 11 CSS;\       956                      1288              SMD                   −0.42 (−0.57 to −0.27)   \<0.00001     0.00         59         0.12         No
                                                                                                                                                               6 CCS                                                                                                                                                             

   Xiong *et al* [@R64]                         Henoch-Schonlein purpura                     R; UBT; IgG; *H. pylori* antigen                                  10 CCS               1309                     500               OR                    3.46 (2.68 to 4.47)      0             0.06         46         0.03         Yes

   Su *et al* [@R52]                            Migraine                                     ^13^C-UBT; ELISA; biopsy                                          5 CCS or CSS         903                      355               OR                    1.92 (1.05 to 3.51)      0.033         0.00         77.4       0.08         yes

   Li *et al* [@R40]                            Recurrent aphthous stomatitis                PCR; UBT                                                          7 CCS                510                      154               OR                    1.85 (1.24 to 2.74)      0.002         0.21         28.5       0.49         No

   Taye *et al* [@R53]                          Atopy                                        H; IgG; ELISA; UBT; SA; IgA                                       2 CS; 3 CCS;\        10 968                   NA                OR                    0.82 (0.73 to 0.91)      \<0.01        0.66         0          0.85         No
                                                                                                                                                               11 CSS                                                                                                                                                            

   Hwang *et al* [@R36]                         Chronic tonsillitis                          R; PCR; culture; CLO                                              6 OS                 436                      NA                OR                    1.99 (0.91 to 4.37)      0.09          0.06         53.6       0.42         No

   Gu *et al* [@R34]                            Chronic urticaria                            ELISA; UBT; S; H; IgG                                             16 CCS               2200                     984               OR                    1.66 (1.12 to 2.45)      0.022         \<0.0001     66         0.01         Yes

   Yao *et al* [@R66]                           Multiple sclerosis                           ELISA; WB; CIA\                                                   9 CCS                2806                     782               OR                    0.73 (0.56 to 0.96)      0             0.05         48         0.07         yes
                                                                                             IF                                                                                                                                                                                                                                  

   Dou *et al* [@R31]                           Halitosis                                    R; H; BUT; culture; PCR;\                                         6 CCS;1 CSS          2312                     467               OR                    4.03 (1.41 to 11.5)      0.009         \<0.0001     89         0.05         Yes
                                                                                             Gram stain; ELISA; SA; endoscopy; CLO                                                                                                                                                                                               

   Jørgensen *et al* [@R38]                     Rosacea                                      NA                                                                14 OS                2455                     1268              OR                    1.74 (1.03 to 2.93)      0.039         0.00         85.6       0.09         yes

   Chen *et al* [@R29]                          Sjogren's syndrome                           Biopsy; ELISA;\                                                   9 CCS                2018                     1054              OR                    1.19 (1.01 to 1.41)      0.033         0.86         0          0.77         No
                                                                                             IgG                                                                                                                                                                                                                                 

   Yong *et al* [@R68]                          Psoriasis                                    IgG; ELISA; UBT; SA                                               4 CSS; 3 PCS;\       1546                     728               OR                    1.58 (1.02 to 2.46)      0.041         0.00         64         0.03         Yes
                                                                                                                                                               2 CCS                                                                                                                                                             

   Yong *et al* [@R69]                          Systemic sclerosis                           IgG; ELISA; IgM; ^13^C-UBT; R                                     7 CSS; 1 PCS         1446                     749               OR                    2.11 (1.62 to 2.76)      0.00          0.33         13         0.84         No
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*p value of significance level.

†p value of Q test.

‡p value for Egger's test.

§The publication bias was assessed using funnel plot.

¶ prevalence or incidence unless otherwise specified.

A, antibody; CagA, cytotoxin-associated gene A; CCS, case--control study; CI, confidence intervals; CLIA, chemiluminescent immunoassay; CLO, *Campylobacter*-like organism test; COPD, chronic obstructive pulmonary disease; CS, cohort study; CSS, cross-sectional study; DM, diabetes mellitus; EAC, oesophageal adenocarcinoma; EIA, enzyme immunoassay; ESCC, oesophageal squamous cell carcinoma; ESRD, end-stage renal disease; GERD, gastro-oesophageal reflux disease; H, histology; HDL-C, high-density lipoprotein cholesterol; H&E, Hematoxylin and eosin stain; His +, positive histological examination of tissue samples; HOMA-IR, homeostatic model assessment of insulin resistance; HP, *H. pylori*; HpSe ^+^, seropositivity for antibodies to whole cell; IF, immunofluorescence; IHD, ischaemic heart disease; MD, mean difference; NA, not applicable; NAFLD, non-alcoholic fatty liver disease; NCCS, nested case-control study; NR, not reported; OS, observational study; PCR, polymerase chain reaction; PCS, prospective cohort study; PNCS, prospective nested cohort study; R, rapid urease test; RCCS, retrospective case--control study; RCSS, retrospective cross-sectional study; RR, relative rate; S, serology; SA, stool antigen; several, several methods; SMD, standard mean difference; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; U, rapid urease test; UBT, urea breath test; WB, western blot.

###### 

Association between *H. pylori* infection and diverse diseases based on study region

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study region    Associations between *H. pylori* infection and outcomes                                                                                                                                                                                                                                                                                                                                               No association with                                                                   
  --------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Europe          Cholangiocarcinoma,[@R14] colorectal, cancer,[@R75]\                                                                                                                                                                                                                                                                                                                                                  Barrett\'s oesophagus[@R32]                                                           Arrhythmia,[@R65] asthma,[@R16] biliary lithiasis,[@R73] migraine,[@R52] recurrent aphthous stomatitis,[@R40] chronic urticaria[@R34]
                  diabetes mellitus,[@R39] diabetic nephropathy,[@R56] alcoholic cirrhosis,[@R33] Parkinson's disease[@R50]                                                                                                                                                                                                                                                                                                                                                                                   

  America         Colorectal cancer,[@R75] biliary lithiasis,[@R73] chronic urticaria[@R34]                                                                                                                                                                                                                                                                                                                             Barrett's oesophagus,[@R32] asthma,[@R16] asthma[@R16]                                Arrhythmia,[@R65] diabetes mellitus,[@R39] alcoholic cirrhosis,[@R33] recurrent aphthous stomatitis[@R40]

  East\           Cholangiocarcinoma,[@R14] colorectal cancer,[@R75] colon neoplasia,[@R28] arrhythmia,[@R65] diabetes mellitus,[@R39] diabetic nephropathy,[@R56] biliary lithiasis,[@R73] ammonia levels in cirrhotic patients,[@R37] chronic cholecystitis and cholelithiasis,[@R27] Parkinson's disease,[@R50] open-angle glaucoma,[@R71] Henoch-Schonlein purpura,[@R64] migraine,[@R52] chronic urticaria[@R34]   Oesophageal squamous cell carcinoma,[@R13] Barrett's oesophagus,[@R32] asthma[@R16]   Myocardial infarction,[@R15] COPD,[@R57] biliary lithiasis,[@R73] peptic ulcer disease,[@R10] alcoholic cirrhosis,[@R33] recurrent aphthous stomatitis,[@R40] multiple sclerosis[@R66]
  (Asia, China)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  West            Colon neoplasia,[@R28] myocardial infarction,[@R15] COPD,[@R57] peptic ulcer disease,[@R10] open-angle glaucoma[@R71]                                                                                                                                                                                                                                                                                 Oesophageal adenocarcinoma,[@R13] asthma,[@R16] multiple sclerosis[@R66]              Oesophageal squamous cell carcinoma,[@R13] ammonia levels in cirrhotic patients[@R37]

  Africa          Arrhythmia[@R65]                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Barrett's oesophagus,[@R32] diabetes mellitus,[@R39] peptic ulcer disease[@R10]

  Australia                                                                                                                                                                                                                                                                                                                                                                                                             Barrett's oesophagus[@R32]                                                             

  Oceania                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Biliary lithiasis[@R73]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease.

Summary effect size {#s3-2}
-------------------

[Table 1](#T1){ref-type="table"} shows the summary effects of the included meta-analysis. Of the 88 outcomes, 74 (84%) had nominal significance (p\<0.05). Of these outcomes, 61 (82%) were harmful associations enumerated as follows: 8 (67%) meta-analyses in cancer outcomes, 6 (75%) in cardiovascular and cerebrovascular diseases, 2 (67%) in respiratory disorders, 6 (60%) in endocrine diseases, 1 (50%) in urological diseases, 12 (67%) in digestive disorders, 4 (80%) in neurocognitive disorders, 6 (67%) in pregnancy-related disorders, 1 (50%) in ophthalmic diseases, 3 (100%) in thyroid diseases, 3 (100%) in haematological disorders and 9 (69%) in other outcomes. These associations had significant pooled estimates (p\<0.05). Thus, *H. pylori* infection was associated with an increased risk of disease and harmful to human health ([table 3](#T3){ref-type="table"}). By contrast, 13 (15%) evidence from meta-analyses were beneficial associations enumerated as follows: 1 (33%) meta-analyses in respiratory disorders, 2 (15%) in cancer outcomes, 1 (10%) endocrine disease, 1 (50%) urological disease, 5 (28%) digestive disorders and 3 (23%) in other outcomes. These associations had significant pooled estimates (p\<0.05), indicating that *H. pylori* infection was related to a decreased risk of some diseases. These findings could be beneficial to human health in some situations ([table 3](#T3){ref-type="table"}).

###### 

Results of evidence quality for all outcomes classified by GRADE

  Level of evidence   Outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  High                --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   --                                                                                                                                                                                                                                                                                                        --
  Moderate            Chronic cholecystitis and cholelithiasis,[@R27] gestational diabetes mellitus,[@R72] gastric cancer[@R12] and systemic sclerosis[@R69]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Triglyceride level[@R54]                                                                                             Inflammatory bowel disease[@R17]                                                                                                                                                                                           --                                                                             Stillbirth[@R72]
  Low                 Hepatocellular carcinoma,[@R13] biliary lithiasis,[@R73] peptic ulcer disease,[@R10] chronic hepatitis C,[@R60] non-alcoholic fatty liver disease,[@R63] diabetic neuropathy,[@R55] Parkinson's disease,[@R50] hyperemesis gravidarum,[@R45] fetal growth restriction,[@R72] spontaneous abortion,[@R72] birth defect,[@R72] open-angle glaucoma,[@R71] autoimmune thyroid diseases,[@R67] Grave's disease,[@R67] Hashimoto's thyroiditis,[@R67] Henoch-Schonlein purpura,[@R64] colorectal adenomatous polyp,[@R58] Sjogren's syndrome,[@R29] duodenal ulcer,[@R12] laryngeal carcinoma,[@R74] chronic obstructive pulmonary disease,[@R57] diabetic nephropathy,[@R56] gastric ulcer,[@R12] alcoholic cirrhosis in Europian,[@R33] cerebral ischaemia[@R47]   Ammonia levels in patients with cirrhosis[@R37]                                                                      Oesophageal adenocarcinoma in the overall population,[@R18] eosinophilic oesophagitis,[@R49] oesophageal eosinophilia,[@R49] atopy[@R53]                                                                                   --                                                                             Diabetic ischemic heart disease, ^55^ fasting blood glucose[@R54] and diabetic ischaemic heart disease[@R56]
  Very low            Lung cancer,[@R44] cholangiocarcinoma,[@R14] chronic tonsillitis,[@R36] colorectal cancer, colon neoplasia,[@R28] ischaemic heart disease,[@R47] myocardial infarction,[@R15] coronary heart disease,[@R48] arrhythmia,[@R65] chronic bronchitis,[@R57] metabolic syndrome,[@R54] diabetes mellitus,[@R39] type 2 diabetes mellitus,[@R39] chronic atrophic gastritis,[@R11] dyspepsia,[@R9] chronic hepatitis B,[@R59] ischaemic stroke,[@R61] dementia,[@R51] pre-eclampsia,[@R72] iron deficiency anaemia,[@R35] iron deficiency,[@R31] anaemia,[@R26] migraine,[@R52] recurrent aphthous stomatitis,[@R40] chronic urticaria,[@R34] halitosis,[@R31] rosacea[@R38] and psoriasis[@R68]                                                                      Carotid intima thickness,[@R76] body mass index[@R54] and homeostatic model assessment of insulin resistance[@R54]   Oesophageal squamous cell carcinoma in Eastern populations,[@R18] Barrett's oesophagus,[@R32] asthma,[@R16] end-stage renal disease in adult,[@R62] multiple sclerosis[@R66] and gastro-oesophageal reflux disease[@R30]   High-density lipoprotein cholesterol,[@R54] circulating ghrelin levels[@R46]   Oesophagogastric junction adenocarcinoma,[@R42] pancreatic cancer,[@R41] systolic blood prssure,[@R54] atherosclerosis,[@R43] type 1 diabetes mellitus,[@R39] alcoholic cirrhosis in all populations,[@R28] stroke,[@R70] low birth weight,[@R72] premature delivery[@R72] and diabetic retinopathy[@R70]

Heterogeneity and publication bias of the included studies {#s3-3}
----------------------------------------------------------

All of the included meta-analyses presented the results of heterogeneity between studies ([table 1](#T1){ref-type="table"}). In particular, 24 (27%) outcomes of meta-analyses showed no heterogeneity between studies (p≥0.1 of Q test), whereas 64 (73%) exhibited significant heterogeneity (p\<0.1 of Q test). Moreover, 32 (57%) of 64 meta-analyses showed moderate to high heterogeneity (I^2^=50%--75%), and 24 (43%) showed high heterogeneity (I^2^\>75%). Among 88 meta-analyses, 68 (77%) demonstrated no statistical evidence on publication bias according to Egger's, whereas 18 (20%) of the meta-analyses presented publication bias (p\<0.1 of Egger's test). Only 2 (2%) meta-analyses did not report publication bias.

Summary of the methodological quality of the included meta-analyses {#s3-4}
-------------------------------------------------------------------

The methodological qualities of the 60 included articles were assessed using AMSTAR 2, and the results are shown in [table 4](#T4){ref-type="table"}. A total of 52 (87%) meta-analyses did not report a predefined explicit statement or protocol; only 8 (13%) meta-analyses were conducted using a comprehensive literature search strategy, and 24 (40%) meta-analyses did not perform a duplicate selection. Twelve (20%) meta-analyses did not conduct a duplicate data extraction, 53 (88%) meta-analyses provided a list of excluded studies but did not justify the exclusions, 6 (10%) meta-analyses did not provide a list of excluded studies, 50 (83%) meta-analyses partially described the included studies and 22 (37%) meta-analyses did not assess the risk of bias in the included studies. Furthermore, none of the meta-analyses reported the details of funding sources for the included studies, and 28 (47%) meta-analyses did not report potential sources of conflicts of interest. Overall, 85 (97%) methodological qualities of the included meta-analyses were categorised as 'critically low', and only 3 (3%) methodological qualities of the included meta-analyses were assessed as low quality ([figure 4](#F4){ref-type="fig"}).

![Map of results of AMSTAR 2: percentage of outcomes per outcome category for 88 meta-analyses.](bmjopen-2019-031951f04){#F4}

###### 

Detail of results for AMSTAR 2 assessing

  Included meta-analyses               AMSTAR 2 checklist   Overall assessment quality                                                                                                              
  ------------------------------------ -------------------- ---------------------------- ----- ------------- ----- ----- ------------- ------------- ----- ---- ----- ----- ----- ----- ----- ----- ----------------
  Xuan *et al* [@R13]                  Yes                  No                           Yes   Yes           Yes   Yes   No            Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Mounika[@R44]                        Yes                  No                           Yes   Partial yes   No    No    Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Xie *et al* [@R18]                   Yes                  No                           Yes   No            Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Wang *et al* [@R58]                  Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Xiao *et al* [@R14]                  Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Dong and Hao[@R75]                   Yes                  No                           Yes   Partial yes   No    No    Partial yes   Partial yes   No    No   No    No    Yes   Yes   Yes   No    Critically low
  Zhou *et al* [@R74]                  Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Liu[@R28]                            Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Li *et al* [@R12]                    Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   Yes   Yes   Critically low
  Ma *et al* [@R42]                    Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Liu *et al* [@R41]                   Yes                  No                           Yes   No            Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Erőss *et al* [@R32]                 Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Low
  Pasceri *et al* [@R47]               Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Liu *et al* [@R15]                   Yes                  No                           Yes   Partial yes   Yes   Yes   No            Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Chen *et al* [@R48]                  Yes                  No                           Yes   Partial yes   No    Yes   No            Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Saburi *et al* [@R43]                Yes                  No                           Yes   Partial yes   No    No    Partial yes   Partial yes   Yes   No   Yes   No    Yes   No    Yes   Yes   Critically low
  Yan *et al* [@R65]                   Yes                  No                           Yes   Yes           Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Dong *et al* [@R76]                  Yes                  No                           No    Yes           No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Wang *et al* [@R57]                  Yes                  No                           Yes   Partial yes   No    Yes   No            Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Chen *et al* [@R16]                  Yes                  No                           Yes   No            Yes   Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Upala *et al* [@R54]                 Yes                  Yes                          Yes   Partial yes   No    Yes   No            Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Li *et al* [@R39]                    Yes                  No                           Yes   Yes           No    No    Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Wang *et al* [@R56]                  Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Wijarnpreecha *et al* [@R62]         Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   No    No    Yes   No    Critically low
  Cremonini *et al* [@R30]             Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Weck and Brenner[@R11]               Yes                  No                           No    No            No    No    Partial yes   Yes           No    No   Yes   No    Yes   Yes   Yes   No    Critically low
  Zhou *et al* [@R73]                  Yes                  No                           Yes   Yes           Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Shiota *et al* [@R10]                Yes                  No                           Yes   Partial yes   Yes   No    Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Jiang *et al* [@R37]                 Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Ford *et al* [@R9]                   Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Feng *et al* [@R33]                  Yes                  No                           Yes   Partial yes   No    No    Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   Yes   No    Critically low
  Wu *et al* [@R17]                    Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   Yes   No    Critically low
  Wang *et al* [@R60]                  Yes                  No                           Yes   Yes           Yes   Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Wang *et al* [@R59]                  Yes                  No                           Yes   Yes           Yes   No    Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Wijarnpreecha *et al* [@R63]         Yes                  No                           Yes   Yes           Yes   Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Cen *et al* [@R27]                   Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Shah *et al* [@R49]                  Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Wang *et al* [@R55]                  Yes                  No                           No    Partial yes   Yes   Yes   No            Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Wang *et al* [@R61]                  Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Yu *et al* [@R70]                    Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Yes           Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Shindler-Itskovitch *et al* [@R51]   Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Yes           No    No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Shen *et al* [@R50]                  Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Ng *et al* [@R45]                    Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   Yes   Yes   Critically low
  Zhan *et al* [@R72]                  Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Zeng *et al* [@R71]                  Yes                  No                           Yes   Partial yes   No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Nweneka and Prentice[@R46]           Yes                  No                           Yes   Partial yes   No    No    Yes           Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Xiong *et al* [@R64]                 Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Low
  Su *et al* [@R52]                    Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Li *et al* [@R40]                    Yes                  No                           Yes   No            Yes   No    Partial yes   Partial yes   Yes   No   Yes   No    Yes   Yes   Yes   Yes   Critically low
  Taye *et al* [@R53]                  Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Low
  Hwang *et al* [@R36]                 Yes                  No                           No    Partial yes   Yes   No    Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   Yes   Yes   Critically low
  Gu *et al* [@R34]                    Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   Yes   Critically low
  Yao *et al* [@R66]                   Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Dou *et al* [@R31]                   Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   No    No   Yes   No    Yes   Yes   No    No    Critically low
  Jørgensen *et al* [@R38]             Yes                  No                           Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   No    Yes   Yes   Yes   Yes   Critically low
  Hou *et al* [@R67]                   Yes                  No                           Yes   Partial yes   No    No    Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   No    Yes   Yes   Critically low
  Hudak *et al* [@R35]                 Yes                  Yes                          Yes   Partial yes   No    Yes   Partial yes   Partial yes   Yes   No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Chen *et al* [@R29]                  Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   No    No   Yes   Yes   Yes   Yes   Yes   No    Critically low
  Yong *et al* [@R68]                  Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   No    Yes   No    Yes   Yes   Critically low
  Yong *et al* [@R69]                  Yes                  Yes                          Yes   Partial yes   Yes   Yes   Partial yes   Partial yes   Yes   No   Yes   No    Yes   No    Yes   No    Critically low

AMSTAR 2 checklists: No.1: Did the research questions and inclusion criteria for the review include the components of PICO? No.2: Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? No. 3: Did the review authors explain their selection of the study designs for inclusion in the review? No. 4: Did the review authors use a comprehensive literature search strategy? No. 5: Did the review authors perform study selection in duplicate? No. 6: Did the review authors perform data extraction in duplicate? No. 7: Did the review authors provide a list of excluded studies and justify the exclusions? No. 8: Did the review authors describe the included studies in adequate detail? No. 9: Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? No. 10: Did the review authors report on the sources of funding for the studies included in the review? No. 11: If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? No. 12: If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? No. 13: Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? No. 14: Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? No. 15: If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? No. 16: Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Evidence classification of the outcomes {#s3-5}
---------------------------------------

The evidence quality of every outcome was assessed using the GRADE system ([table 5](#T5){ref-type="table"}). None of the evidence quality for any outcome was rated 'high'. Most of the qualities of evidence were downgraded by the potential risk of bias and serious heterogeneity. A total of 32 (36%) evidence qualities of outcomes were rated 'low', 49 (56%) evidence were rated 'very low' and only 7 (8%) evidence were rated 'moderate' ([figure 5](#F5){ref-type="fig"}). [Table 5](#T5){ref-type="table"} shows the results of evidence quality from 88 outcomes.

![Map of results of GRADE: percentage of outcomes per outcome category for 88 evidence.](bmjopen-2019-031951f05){#F5}

###### 

Details of evidence quality for outcomes classified by GRADE

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Included meta-analyses                        Association between H. pylori and\*          Downgrade factors   Upgrade factors   GRADE class                     
  --------------------------------------------- -------------------------------------------- ------------------- ----------------- ------------- ---- ---- --- --- ----------
  Cancer outcomes                                                                                                                                                  

   Xuan *et al* [@R13]                          Hepatocellular carcinoma                     −1                  0                 0             -1   −1   2   1   Low

   Mounika[@R44]                                Lung cancer                                  −1                  −2                0             0    0    1   1   Very low

   Xie *et al* [@R18]                           ESCC in Eastern populations                  −1                  −1                0             0    0    0   1   Very low

   Xie *et al* [@R18]                           EAC in the overall population                −1                  0                 0             0    0    0   1   Low

   Wang *et al* [@R58]                          Colorectal adenomatous polyp                 −1                  0                 0             0    0    0   1   Low

   Xiao *et al* [@R14]                          Cholangiocarcinoma                           −1                  −1                0             −1   −1   2   1   Very low

   Dong and Hao[@R75]                           Colorectal cancer                            −1                  −1                0             0    0    0   1   Very low

   Zhou *et al* [@R74]                          Laryngeal carcinoma                          −1                  −1                0             0    0    1   1   Low

   Liu[@R28]                                    Colon neoplasia                              −1                  −2                0             0    0    0   1   Very low

   Li *et al* [@R12]                            Gastric cancer                               −1                  0                 0             0    0    1   1   Moderate

   Ma *et al* [@R42]                            Oesophagogastric junction adenocarcinoma     −1                  −2                0             0    0    0   1   Very low

   Liu *et al* [@R41]                           Pancreatic cancer                            −1                  −2                0             0    0    0   1   Very low

  Cardiovascular and cerebrovascular diseases                                                                                                                      

   Pasceri *et al* [@R47]                       Ischaemic heart disease                      −2                  −1                0             0    0    0   1   Very low

   Pasceri *et al* [@R47]                       Cerebral ischaemia                           −2                  0                 0             0    0    1   1   Low

   Wang *et al* [@R55]                          Diabetic IHD                                 −1                  0                 0             0    0    0   1   Low

   Liu *et al* [@R15]                           Myocardial infarction                        −1                  −2                0             0    0    0   1   Very low

   Chen *et al* [@R48]                          Coronary heart disease                       −2                  −2                0             0    0    0   1   Very low

   Ramezani-Binabaj *et al* [@R43]              Atherosclerosis                              −2                  −1                0             −1   −1   0   1   Very low

   Yan *et al* [@R65]                           Arrhythmia                                   −1                  −2                0             0    0    0   1   Very low

   Dong *et al* [@R76]                          Carotid intima thickness                     −1                  −2                0             0    0    0   1   Very low

  Respiratory disorders                                                                                                                                            

   Wang *et al* [@R57]                          COPD                                         −1                  −1                0             0    0    1   1   Low

   Wang *et al* [@R57]                          Chronic bronchitis                           −1                  −1                0             0    0    0   1   Very low

   Chen *et al* [@R16]                          Asthma                                       −1                  −1                0             0    0    0   1   Very low

  Endocrine disease                                                                                                                                                

   Upala *et al* [@R54]                         Metabolic syndrome                           −1                  −1                0             0    0    0   1   Very low

   Upala *et al* [@R54]                         Fasting blood glucose                        −1                  −1                0             0    0    1   1   Low

   Upala *et al* [@R54]                         HDL-C                                        −1                  −2                0             0    0    1   1   Very low

   Upala *et al* [@R54]                         Triglyceride level                           −1                  −1                0             0    0    2   1   Moderate

   Upala *et al* [@R54]                         Systolic blood pressure                      −1                  −2                0             0    0    1   1   Very low

   Upala *et al* [@R54]                         Body mass index                              −1                  −1                0             0    0    0   1   Very low

   Upala *et al* [@R54]                         HOMA-IR                                      −1                  −2                0             0    0    0   1   Very low

   Li *et al* [@R39]                            DM                                           −1                  −2                0             0    −1   0   1   Very low

   Li *et al* [@R39]                            T2DM                                         −1                  −2                0             0    −1   1   1   Very low

   Li *et al* [@R39]                            T1DM                                         −1                  −2                0             0    0    0   1   Very low

  Urological disease                                                                                                                                               

   Wang[@R56]                                   Diabetic nephropathy                         −1                  0                 0             0    0    0   1   Low

   Wijarnpreecha *et al* [@R62]                 ESRD in adult                                −1                  −2                0             0    0    0   1   Very low

  Digestive disorders                                                                                                                                              

   Erőss *et al* [@R32]                         Barrett's oesophagus                         −1                  −2                0             0    −1   0   1   Very low

   Li *et al* [@R12]                            Gastric ulcer                                −1                  0                 0             0    0    0   1   Low

   Li *et al* [@R12]                            Duodenal ulcer                               −1                  −1                0             0    0    1   1   Low

   Cremonini *et al* [@R30]                     GERD in population with HP-negative status   −1                  −1                0             0    0    0   1   Very low

   Weck and Brenner[@R11]                       Chronic atrophic gastritis                   −1                  −2                0             0    −1   2   1   Very low

   Zhou *et al* [@R73]                          Biliary lithiasis                            −1                  −1                0             0    0    1   1   Low

   Shiota *et al* [@R10]                        Peptic ulcer disease                         −1                  0                 0             0    0    0   1   Low

   Jiang *et al* [@R37]                         Ammonia levels in cirrhotic patients         −1                  0                 0             0    0    0   1   Low

   Ford *et al* [@R9]                           Dyspepsia                                    −1                  −1                0             0    0    0   1   Very low

   Feng *et al* [@R33]                          Alcoholic cirrhosis in all population        −1                  −2                0             0    0    0   1   Very low

   Feng *et al* [@R33]                          Alcoholic cirrhosis in European              −1                  0                 0             −1   0    1   1   Low

   Wu *et al* [@R17]                            Inflammatory bowel disease                   −1                  0                 0             0    0    1   1   Moderate

   Wang *et al* [@R60]                          Chronic hepatitis C                          −1                  −1                0             0    0    1   1   Low

   Wang *et al* [@R59]                          Chronic hepatitis B                          −1                  −2                0             0    −1   1   1   Very low

   Wijarnpreecha *et al* [@R63]                 NAFLD                                        −1                  0                 0             0    0    0   1   Low

   Cen *et al* [@R27]                           Chronic cholecystitis and cholelithiasis     −1                  0                 0             0    0    1   1   Moderate

   Shah *et al* [@R49]                          Eosinophilic oesophagitis                    0                   −1                0             0    0    0   1   Low

   Shah *et al* [@R49]                          Oesophageal eosinophilia                     0                   −1                0             0    0    0   1   Low

  Neurocognitive disorders                                                                                                                                         

   Wang *et al* [@R55]                          Diabetic neuropathy                          −1                  0                 0             0    0    0   1   Low

   Wang *et al* [@R61]                          Ischaemic stroke                             −1                  −1                0             0    −1   0   1   Very low

   Yu *et al* [@R70]                            Stroke                                       −1                  −1                0             0    0    0   1   Very low

   Shindler-Itskovitch\                         Dementia                                     −1                  −2                0             0    0    0   1   Very low
  *et al* [@R51]                                                                                                                                                   

   Shen *et al* [@R50]                          Parkinson's disease                          0                   0                 0             0    −1   0   1   Low

  Pregnancy-related disorders                                                                                                                                      

   Ng *et al* [@R45]                            Hyperemesis gravidarum                       −1                  0                 0             0    0    0   1   Low

   Zhan *et al* [@R72]                          Pre-eclampsia                                −1                  −1                0             0    −1   1   1   Very low

   Zhan *et al* [@R72]                          Fetal growth restriction                     −1                  −1                0             0    0    1   1   Low

   Zhan *et al* [@R72]                          Gestational DM                               −1                  0                 0             0    0    1   1   Moderate

   Zhan *et al* [@R72]                          Spontaneous abortion                         −1                  0                 0             0    0    0   1   Low

   Zhan *et al* [@R72]                          Birth defect                                 −1                  0                 0             0    0    0   1   Low

   Zhan *et al* [@R72]                          Stillbirth                                   −1                  0                 0             0    0    1   1   Moderate

   Zhan *et al* [@R72]                          Low birth weight                             −1                  −1                0             0    0    0   1   Very low

   Zhan *et al* [@R72]                          Premature delivery                           −1                  −1                0             0    0    0   1   Very low

  Ophthalmic diseases                                                                                                                                              

   Wang *et al* [@R55]                          Diabetic retinopathy                         −1                  −1                0             0    0    0   1   Very low

   Zeng *et al* [@R71]                          Open-angle glaucoma                          −1                  −1                0             0    0    1   1   Low

  Thyroid disease                                                                                                                                                  

   Hou *et al* [@R67]                           Autoimmune thyroid diseases                  −1                  −1                0             0    0    1   1   Low

   Hou *et al* [@R67]                           Grave's disease                              −1                  −1                0             0    0    1   1   Low

   Hou *et al* [@R67]                           Hashimoto's thyroiditis                      −1                  −1                0             0    0    1   1   Low

  Homeopathy disorders                                                                                                                                             

   Hudak *et al* [@R35]                         Iron deficiency anaemia                      −1                  −1                0             0    0    0   1   Very low

   Hudak *et al* [@R35]                         Iron deficiency                              −1                  −1                0             0    0    0   1   Very low

   Hudak *et al* [@R35]                         Anaemia                                      −1                  −1                0             0    0    0   1   Very low

  Other outcomes                                                                                                                                                   

   Nweneka and Prentice[@R46]                   Circulating ghrelin levels                   −1                  −1                0             0    0    0   1   Very low

   Xiong *et al* [@R64]                         Henoch-Schonlein purpura                     −1                  0                 0             0    −1   1   1   Low

   Su *et al* [@R52]                            Migraine                                     −1                  −1                0             0    -1   0   1   Very low

   Li *et al* [@R40]                            Recurrent aphthous stomatitis                −1                  0                 0             −1   0    0   1   Very low

   Taye *et al* [@R53]                          Atopy                                        −1                  0                 0             0    0    0   1   Low

   Hwang *et al* [@R36]                         Chronic tonsillitis                          −1                  −1                0             0    0    0   1   Very low

   Gu *et al* [@R34]                            Chronic urticaria                            −1                  −1                0             0    −1   0   1   Very low

   Yao *et al* [@R66]                           Multiple sclerosis                           −1                  0                 0             0    -1   0   1   Very low

   Dou *et al* [@R31]                           Halitosis                                    −1                  −2                0             0    −1   0   1   Very low

   Jørgensen *et al* [@R38]                     Rosacea                                      −1                  −2                0             0    0    0   1   Very low

   Chen *et al* [@R29]                          Sjogren's syndrome                           −1                  0                 0             0    0    0   1   Low

   Yong *et al* [@R68]                          Psoriasis                                    −1                  −1                0             0    −1   0   1   Very low

   Yong *et al* [@R69]                          Systemic sclerosis                           −1                  0                 0             0    0    1   1   Moderate
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reference: −1 means downgrade one level; −2 means downgrade two levels; 1 means upgrade one level.

\* prevalence or incidence unless otherwise specified.

COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DM, diabetes mellitus; EAC, oesophgeal adenocarcinoma; ESCC, oesophageal squamous cell carcinoma; ESRD, end-stage renal disease; GERD, gastro-oesophageal reflux disease; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, hemeostatic model assessment of insulin resistance; HP, H. pylori; IHD, ischemic heart disease; NAFLD, non-alcoholic fatty liver disease; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

Harmful outcomes associated with *H. pylori* infection {#s3-6}
------------------------------------------------------

Our confidence level in the following was moderate: *H. pylori* infection is associated with an increased risk of chronic cholecystitis and cholelithiasis,[@R27] gestational diabetes mellitus,[@R72] systemic sclerosis[@R69] and gastric cancer,[@R12] and increased serum triglyceride level.[@R54] Our confidence level in the following was low: *H. pylori* infection is associated with an increased risk of HCC,[@R13] biliary lithiasis,[@R73] PUD,[@R10] duodenal ulcer,[@R12]chronic hepatitis C,[@R60] non-alcoholic fatty liver disease,[@R63] diabetic neuropathy,[@R55] Parkinson's disease,[@R50] hyperemesis gravidarum,[@R45] fetal growth restriction,[@R72] spontaneous abortion,[@R72] birth defect,[@R72] open-angle glaucoma,[@R71] autoimmune thyroid diseases,[@R67] Grave's disease,[@R67] Hashimoto's thyroiditis,[@R67] Henoch-Schonlein purpura,[@R64] diabetic nephropathy,[@R56] gastric ulcer,[@R12] alcoholic cirrhosis Europeans,[@R33] and Sjogren's syndrome[@R29]; ammonia levels decrease in patients with cirrhosis.[@R37] Our confidence level in the following was very low: *H. pylori* infection is associated with an increased risk of lung cancer,[@R44] cholangiocarcinoma,[@R14] colorectal cancer[@R75], colon neoplasia,[@R28] chronic tonsillitis,[@R36] ischaemic heart disease,[@R47] MI,[@R15] coronary heart disease,[@R48] arrhythmia,[@R65] chronic bronchitis,[@R57] metabolic syndrome,[@R54] diabetes mellitus,[@R39] type 2 diabetes mellitus,[@R39] chronic atrophic gastritis,[@R11] dyspepsia,[@R9] chronic hepatitis B,[@R59] ischaemic stroke,[@R61] dementia,[@R51] pre-eclampsia,[@R72] iron deficiency anaemia,[@R35] iron deficiency,[@R31] anaemia,[@R26] migraine,[@R52] recurrent aphthous stomatitis,[@R40] chronic urticaria,[@R34] halitosis,[@R31] rosacea,[@R38] laryngeal carcinoma,[@R74] cerebral ischaemia,[@R47] chronic obstructive pulmonary disease[@R57] and psoriasis[@R68]; an increase in the following parameters is observed: carotid intima thickness,[@R76] body mass index[@R54] and homeostatic model assessment of insulin resistance.[@R54]

Beneficial outcomes associated with *H. pylori* infection {#s3-7}
---------------------------------------------------------

Our confidence level in the following was moderate: *H. pylori* infection is associated with a decreased risk of irritable bowel syndrome.[@R17] Our confidence level in the following was low: *H. pylori* infection is associated with a decreased risk of oesophageal adenocarcinoma in the overall population,[@R18] colorectal adenomatous polyp,[@R58] eosinophilic oesophagitis,[@R49] oesophageal eosinophilia[@R49] and atopy[@R53]. Our confidence level in the following was very low: *H. pylori* infection is associated with a decreased risk of oesophageal squamous cell carcinoma in Eastern populations,[@R18] Barrett's oesophagus,[@R32] asthma,[@R16] end-stage renal disease in adults,[@R62] multiple sclerosis[@R66] and gastro-oesophageal reflux disease[@R30]; decreasing high-density lipoprotein cholesterol[@R54] and circulating ghrelin levels are also observed.[@R46]

Discussion {#s4}
==========

Principal findings and possible explanations {#s4-1}
--------------------------------------------

This umbrella review summarised the current existing evidence from meta-analyses on the associations between *H. pylori* infection and diverse health outcomes. In this umbrella review, 60 publications of interest were systematically reviewed. The role of *H. pylori* infection was explored in relation to a wide range of diseases (74 in total), including cancers, cardiovascular and cerebrovascular diseases, respiratory disorders, endocrine diseases, urological diseases, digestive disorders, neurocognitive disorders, pregnancy-related disorders, ophthalmic diseases, thyroid disease, haematological disorders and other outcomes ([figure 3](#F3){ref-type="fig"}). *H* *. pylori* infection is likely more harmful in Asians by increasing the risk of 15 types of diseases ([table 2](#T2){ref-type="table"}). Through this umbrella review, an uptrend of research on the associations between *H. pylori* infection and health outcomes was found ([figure 2](#F2){ref-type="fig"}). However, gaps in studies exploring the association between *H. pylori* infection and the musculoskeletal system diseases were identified as formal meta-analyses were not found. A clear reference exposure time of *H. pylori* infection could not be obtained because all of the meta-analyses did not present this aspect.

A large proportion (84%) of the health outcomes was associated with *H. pylori* infection. However, most of them (64%) had serious heterogeneity between studies. The potential heterogeneity might be due to possible confounding factors (e.g. different *H. pylori* measurement methods, alcohol consumption, smoking, sex, study region, different nationalities and time of follow-up). Substantial heterogeneity affected the results of meta-analyses, indicating that some associations between *H. pylori* infection and diverse health outcomes might be inflated or false positives. In addition, some of them 20%) had a notable publication bias, revealing that some negative results were not reported. In practice, associations between *H. pylori* infection and diseases might be found in thousands of individuals. However, only a small proportion of associations were recorded, and an even smaller fraction was finally published. Positive results were probably more easily published than negative results that might not be even published. If researchers strongly believed in the association between *H. pylori* infection and the risk of developing diseases, their work might be under pressure to comply with the hypothesis during publication. These requirements could cause publication biases in the results. Our result showed that 97% of the meta-analyses had 'critically low' methodological quality ([figure 4](#F4){ref-type="fig"}). Evidence was downgraded by serious heterogeneity, potential bias and low method quality. Hence, none of the outcomes had high-quality evidence after evaluation based on the evidence classification criteria. Based on this metric, moderate-quality evidence only existed in six health outcomes, suggesting that *H. pylori* infection was probably associated with an increased risk of hypertriglyceridemia, chronic cholecystitis and cholelithiasis, gestational diabetes mellitus, gastric cancer and systemic sclerosis and a decreased risk of irritable bowel syndrome. Among these risks, the outcome of triglyceride level exhibited moderate heterogeneity (I^2^=71%), demonstrating that this association should be cautiously interpreted. This umbrella reivew shows there is no association between *H.ylori* infection and risk of stillbirth.

Strengths and limitations of the umbrella review {#s4-2}
------------------------------------------------

Our umbrella review has several great strengths. An umbrella review systematically searches, collects and assesses the strength and credibility of the evidence derived from various systematic reviews and meta-analyses on any clinical health outcomes related to a particular exposure.[@R77] Studies have also revealed the strengths and significance of umbrella reviews in detail.[@R78] Considering that the associations between *H. pylori* infection and diverse health outcomes have not been systematically and comprehensively assessed, this umbrella review comprehensively evaluated the methodological quality of meta-analyses and assessed the evidence quality of outcomes from the published meta-analyses of observational studies. The quality of the included studies in meta-analyses affects the quality of the meta-analyses. When possible, we reanalysed the summary estimates and explored the heterogeneity and publication bias of the included meta-analyses by using a standardised method. In this umbrella review, seven databases were comprehensively and systematically searched using a standard search strategy to identify eligibility. An uptrend of studies on associations between *H. pylori* infection and various health outcomes was found, indicating that the associations of *H. pylori* infection and diseases were widely explored. However, meta-analyses investigated on associations between *H. pylori* infection and musculoskeletal disorders, and mucosa associated limphoid tissue (MALT) lymphoma were not found in our scope.

We used AMSTAR 2, which is a standard methodological quality assessment approach, to assess the quality of the method used for meta-analyses. Since AMSTAR 2 was developed from AMSTAR in 2017, it has been considered a valid and reliable methodological quality assessment tool.[@R19] The lengths of AMSTAR 2 have been described in other studies.[@R21] This tool helped us identify the highest methodological quality of the meta-analyses of RCTs and also the meta-analyses of observational studies. Therefore, AMSTAR 2 is more practical and applicable than AMSTAR. In this umbrella review, 95% of the methodological qualities of existing meta-analyses studying the associations between *H. pylori* infection and diverse health outcomes were critically low, suggesting that the results of the meta-analyses might be inconclusive, and further meta-analyses with high methodological quality should be conducted to verify such conclusions.

We also adopted the GRADE system criteria, which are credibility-assessment criteria, to assess the evidence quality of outcomes from meta-analyses. The certainty of evidence is important for the recommendation of guidelines, affecting a patient's outcomes.[@R84] GRADE re-evaluates the quality of evidence and rates the certainty evidence for clinical decision-makers and guideline developers.[@R22] This system is also used worldwide. We downgraded the evidence level because all of the meta-analyses exhibited a potential risk of bias, but we upgraded the evidence level because the result of the included meta-analyses might be affected by various potential confounders, such as age, sex or smoking. Although conducting AMSTAR 2 and GRADE classification was relatively subjective, they were performed by two investigators independently, and the results were checked by another investigator. The inconsistencies were resolved via a discussion, and all discrepancies were arbitrated by another researcher, thereby greatly reducing the subjectivity.

In terms of the study weakness, this umbrella review focused on the existing and published systematic review and meta-analyses and only included publications in Chinese and English. Thus, we might have missed some studies on the associations between *H. pylori* infection and diverse health outcomes. The potential missing data in other languages might affect the evaluation results. In this umbrella review, only systematic reviews and meta-analyses were included. Evidence from individual observational studies involving undeveloped a meta-analysis was not in the scope of our discussion, such as MALT lymphoma.[@R85] This situation might result in conclusion bias of association between *H. pylori* infection and human health. In addition, we could not obtain a clear exposure time because most of the meta-analyses did not present the length of time of *H. pylori* infection. Most of the meta-analyses had heterogeneity, but we did not re-explore the factors causing heterogeneity, such as population characteristics (eg, age, sex and nationality), study design and study region. Common flaws are evident among meta-analyses.[@R86] The evidence quality of meta-analyses depends on the quality of original individual studies included in meta-analyses. However, this umbrella review did not assess the quality of the original individual studies included in the meta-analyses. We extracted the data for calculation from the included meta-analyses but not from the original individual studies, possibly affecting the conclusion of this umbrella review.

Clinical implications and future research {#s4-3}
-----------------------------------------

Clinicians have considered whether individuals should be tested for *H. pylori* or offered eradication therapy for *H. pylori* infection since multiple unfavourable influences on human health related to *H. pylori* infection have been found. Different suggestions on addressing *H. pylori* infection have been provided in different guidelines because of objective factors (eg, local drug resistance, economic level, and medical and health conditions). Several guidelines, including Asian guidelines, recommend screening in every individual, whereas other guidelines recommend no screening.[@R87] The different recommendations regarding *H. pylori* detection and eradication in different guidelines may cause confusion among clinicians. The significance of our study mostly included the summary of the diseases associated with *H. pylori* and the clarification of evidence quality to guide clinical practice.

Our umbrella review found that 69% of outcomes were unfavourable influences on human health which should be paid attention to by clinicians, even though most of them were low-quality evidence. In terms of eradicating therapy for *H. pylori* infection, the beneficial influence (*H. pylori* infection as a protect factor) on human health might be considered by clinicians. This umbrella review found that a decreased risk of 13 types of conditions (eg, inflammatory bowel disease, laryngeal and oesophageal carcinoma) was also found, even though *H. pylori* was associated with an increased risk of a large proportion of diseases. *H. pylori*--eradicating drugs have adverse effects, such as increased resistance of *H. pylori*.[@R88] Therefore, for an individual who tests positive, whether *H. pylori* infection is a risk factor or a protective factor should be distinguished before he/she receives eradicating therapy. Before deciding on administering eradicating therapy, clinicians should weigh the advantages and disadvantages of eradicating *H. pylori* based on an individual's situation.

Future prospective studies on *H. pylori* infection and health outcomes should use time-varying exposure (*H. pylori* infection duration) and confounder information to better model the association between *H. pylori* infection and health outcomes. Data remain scarce, and a large heterogeneity exists in some associations of *H. pylori* infection and diseases. Prospective studies should be carried out to better characterise these associations. In the absence of data from RCTs for *H. pylori* infection and risk of developing diseases, Mendelian randomisation analyses may be useful in determining whether an observed association is likely to be causal. Meta-analyses investigating associations between *H. pylori* infection and some diseases, such as autoimmune liver disease,[@R89] have not been found in our scope. A meta-analysis may be conducted to confirm these conclusions in the future because of the possible inconsistent results in different individual studies.

Conclusion {#s5}
==========

This umbrella review systematically and comprehensively collected a large amount of existing evidence on the associations between *H. pylori* infection and diverse health outcomes from published meta-analyses to help clinical decision-makers, guideline developers and investigators evaluate these associations. Although 60 meta-analyses explored 88 unique outcomes, moderate evidence only existed in six outcomes with statistical significance. *H. pylori* infection may be associated with a decreased risk of irritable bowel syndrome and an increased risk of hypertriglyceridemia, chronic cholecystitis and cholelithiasis, gestational diabetes mellitus, gastric cancer and systemic sclerosis. Further prospective studies and large RCTs with a good assessment of associations between *H. pylori* infection and health outcomes should be conducted to draw a firm conclusion.
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